Supplementary Data 1 from Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors | Synapse
July 1, 2024Open Access
Supplementary Data 1 from Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.